Search results
Results from the WOW.Com Content Network
The first left ventricular assist device (LVAD) system was created by Domingo Liotta at Baylor College of Medicine in Houston in 1962. The first LVAD was implanted in 1963 by Liotta and E. Stanley Crawford. The first successful implantation of an LVAD was completed in 1966 by Liotta along with Dr. Michael E. DeBakey.
EXCOR is a paracorporeal, pulsatile flow VAD. [10] The device provides left ventricular, right ventricular or biventricular assistance. [11] The EXCOR system includes paracorporeal, pneumatically-driven polyurethane blood pumps. Each pump consists of a blood chamber and an air chamber which are separated by a multilayer flexible membrane. [12]
Pump thrombosis is defined as a specific case of a major device malfunction. In turn, device malfunction is as defined by Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) as a failure of one or more of the components of the mechanical circulatory support systems which either directly causes or could potentially induce a state of inadequate circulatory support (low ...
Thoratec's third-generation HeartMate LVAD is the HeartMate 3, [48] [49] designed to lower adverse event rates through improved hemocompatibility, and to increase ease of surgical placement through new design and compact size. [50] [51] It began undergoing clinical trials in the U.S. and internationally in mid 2014. [48] [49] [50] [52] [53]
One parameter to quantify this difference is the pulsatility index (PI), which is equal to the difference between the peak systolic velocity and the minimum diastolic velocity divided by the mean velocity during the cardiac cycle. This value decreases with distance from the heart.
O. H. "Bud" Frazier is a heart surgeon and director of cardiovascular surgery research at the Texas Heart Institute (THI), best known for his work in mechanical circulatory support (MCS) of failing hearts using left ventricular assist devices (LVAD) and total artificial hearts (TAH).
The search engine that helps you find exactly what you're looking for. Find the most relevant information, video, images, and answers from all across the Web.
In order for a patient to be recommended for destination therapy with an LVAD, he/she will have presented with end-stage heart failure, and will be ineligible for a transplant due to age, additional health problems, or other complications. In addition, patients may be eligible but are not suitable for heart transplant because they have other ...